Mechanism of Action - Folate Synthesis Crashers
Sulfonamides and trimethoprim disrupt the bacterial synthesis of tetrahydrofolate (THF), an essential cofactor for purine and DNA synthesis. This sequential blockade is bactericidal.
- Sulfonamides: Structural analogs of PABA (para-aminobenzoic acid).
- Competitively inhibit dihydropteroate synthase.
- Trimethoprim: Structural analog of dihydrofolic acid.
- Inhibits dihydrofolate reductase (DHFR).
📌 Mnemonic: SULFA drugs inhibit Synthase; Trimethoprim inhibits reducTase.
⭐ Humans are unaffected by sulfonamides as we acquire folate from our diet, lacking the PABA pathway. Trimethoprim has a several thousand-fold higher affinity for bacterial DHFR than human DHFR, ensuring selective toxicity.
Clinical Uses - The TMP-SMX Hit List
📌 TMP = Treats Many Pathogens
- Uncomplicated UTIs & Prostatitis
- Respiratory Infections:
- Pneumocystis jirovecii (PJP) - drug of choice for treatment & prophylaxis.
- Community-Acquired MRSA pneumonia.
- GI Infections: Shigella, Salmonella (though resistance is common).
- Encephalitis & Abscesses:
- Toxoplasma gondii (prophylaxis & treatment).
- Nocardia (drug of choice).
- Niche Pathogens: Stenotrophomonas maltophilia.
⭐ Prophylaxis for PJP is initiated in HIV patients when their CD4 count drops below 200 cells/mm³.
Adverse Effects - When Good Drugs Go Bad
Sulfonamides (Sulfa Drugs)
- Hypersensitivity: Rashes, urticaria, fever. Can progress to life-threatening Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN).
- Photosensitivity: Severe sunburns.
- Nephrotoxicity: Crystalluria leading to acute interstitial nephritis. Advise patients to stay hydrated.
- Hematologic:
- Hemolytic anemia in patients with G6PD deficiency.
- Aplastic anemia (rare).
- Kernicterus: In newborns; displaces bilirubin from albumin. Contraindicated in pregnancy (3rd trimester) & neonates.
- Drug Interactions: Potentiates warfarin, phenytoin.
📌 Mnemonic: SULFA
- Stevens-Johnson syndrome
- Urticaria / Urine (crystalluria)
- Leukopenia / Light sensitivity
- Folate deficiency (hematologic)
- Aplastic anemia / Anemia (hemolytic)
⭐ Exam Favorite: Always check for G6PD deficiency before prescribing sulfonamides. The resulting oxidative stress leads to acute hemolytic anemia, presenting with jaundice, dark urine, and fatigue.
Trimethoprim (TMP)
- Hematologic: Megaloblastic anemia, leukopenia, granulocytopenia ("TMP Treats Marrow Poorly").
- Reversible with folinic acid (leucovorin) rescue.
- Metabolic: Hyperkalemia (blocks epithelial sodium channel in collecting duct, similar to amiloride).
- Sulfonamides inhibit dihydropteroate synthase and trimethoprim inhibits dihydrofolate reductase, causing a sequential blockade of folate synthesis.
- The combination (TMP-SMX) is bactericidal and shows strong synergy.
- Primary uses include UTIs, Pneumocystis jirovecii (PJP) pneumonia treatment and prophylaxis, and Nocardia infections.
- Key sulfa toxicities: hypersensitivity (Stevens-Johnson syndrome), hemolysis in G6PD deficiency, and nephrotoxicity (crystalluria).
- Trimethoprim can cause megaloblastic anemia and hyperkalemia.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app
